21st International Congress » Parkinson's Disease: Pathophysiology

Date: Tuesday, June 6, 2017

Time: 1:45pm-3:15pm

Location: Exhibit Hall C

Meeting: 21st International Congress

1:45pm-3:15pm: a-synuclein neurotoxicity and spreading using Lewy Body extracts from Parkinson Disease Brains: In vitro screening by cell-based assays

E. Bezard, F. Cavaliere, L. Cerf, B. Dehay, P. Ramos-Gonzalez, F. De Giorgi, M. Bourdenx, A. Bessede, J. Obeso, F. Ichas, C. Matute (Bordeaux, France)

1:45pm-3:15pm: Admixing augments nigral dopaminergic correlates during development to impart resistance to MPTP-toxicity at adulthood

V. D J, Y. H, R. T R, P. Anand Alladi (Bangalore, India)

1:45pm-3:15pm: Alpha-synuclein enhances histone H3 lysine-9 dimethylation

N. Sugeno, S. Jäckel, A. Voigt, T. Hasegawa, P. Kahle (Tübingen, Germany)

1:45pm-3:15pm: Alpha-Synuclein knock-out mouse brain shows significant dysregulation of c-Fos expression

M. Overhoff, J. Canet-Pons, D. Meierhofer, S. Gispert, G. Auburger (Frankfurt am Main, Germany)

1:45pm-3:15pm: Alpha-synuclein protein homeostasis and oligomerization in iron-overloaded cells expressing mutant HFE

Y. Kim, J. Connor, M. Stahl (Hershey, PA, USA)

1:45pm-3:15pm: Alpha-synucleinopathy and mitochondrial dysfunction in a cell based model of neurodegeneration: Implications in the pathogenesis of sporadic Parkinson’s disease

U. Ganguly, O. Sen, A. Ganguly, S. Chakrabarti (Kolkata, India)

1:45pm-3:15pm: Altered somtatosensory cortex neuronal activity in a rat model of Parkinson`s disease and levodopa-induced dyskinesias

K. Schwabe, X. Jin, J. Krauss, M. Alam (Hannover, Germany)

1:45pm-3:15pm: Analysis of serum non-mercaptoalbumin in patients with Parkinson’s disease

S. Ueno, T. Hatano, Y. Ouji, S. Saiki, H. Ikeda, N. Hattori (Tokyo, Japan)

1:45pm-3:15pm: Anti-synuclein alpha antibodies and IL-1β at Parkinson Disease (PD).

A. Boika, V. Ponomarev, H. Ivanchik (Minsk, Belarus)

1:45pm-3:15pm: Antibody binding differences in alpha-synuclein from Parkinson’s disease and multiple system atrophy

T. Yamasaki, A. Welleford (Lexington, KY, USA)

1:45pm-3:15pm: Assessment of neurodegeneration and spreading of α-synuclein pathology induced by structurally defined α-synuclein assemblies in wild-type mice

E. Bezard, M. Bourdenx, L. Arcuri, L. Bousset, R. Melki, B. Dehay (Bordeaux, France)

1:45pm-3:15pm: Association of CSF biomarkers with motor and non-motor features in moderately advanced Parkinson’s disease cohort: the BioFIND study

J. Goldman, A. Amara, L. Shaw, P. Taylor, H. Andrews, R. Alcalay, T. Xie, P. Tuite, C. Henchcliffe, P. Hogarth, S. Frank, M.-H. Saint Hilaire, A. Naito, M. Frasier, V. Arnedo, A. Reimer, M. Sutherland, C. Swanson-Fischer, K. Gwinn, U. Kang (Chicago, IL, USA)

1:45pm-3:15pm: Axial signs in early-stage Parkinson’s disease : an influence of the genotype ?

G. BAILLE, D. DEVOS, V. HUIN, T. PEREZ, B. SABLONNIERE, L. DEFEBVRE, C. MOREAU (CHRU Lille, France)

1:45pm-3:15pm: Beneficial and Protective Effects of Withania Someniferais On Mice Brain: A Therapeutic Potential Drug for Parkinson’s Disease

S. Rajput, S. Sinha (New Delhi, India)

1:45pm-3:15pm: Brain insulin resistance in Parkinson’s disease

F. Bassil, M.-H. Canron, N. Dutheil, A. Vital, E. Bezard, P.-O. Fernagut, W. Meissner (Bordeaux, France)

1:45pm-3:15pm: Catecholamines’ concentration ratio in plasma of early diagnosed treatment-naive patients with Parkinson disease

Z. Zalyalova, D. Khasanova (Kazan, Russian Federation)

1:45pm-3:15pm: Characterizing the Bcl-2 Associated Athanogene 5 Interactome

E. Friesen, X. Wang, D. Williams, H. Chau, M. De Snoo, O. Pellerito, L. Kalia, G. Schmitt-Ulms, S. Kalia (Toronto, ON, Canada)

1:45pm-3:15pm: Citrus extract A protects dopaminergic neuron by modulating mitochondrial respiration and reactive oxygen species

Y. Jang, J. Han, S.J. Kim, M.J. Lee, I. Ryu, X. Ju, H. Chu, M.J. Ryu, E.S. Oh, S.-Y. Choi, W. Chung, J.Y. Heo, G.R. Kweon (Daejeon, Republic of Korea)

1:45pm-3:15pm: Correction of minimal oculomotor disorders improves forward and lateral axial dystonia in Pakinson’s disease

S. Varanese, M. Meglio, M. Bologna, M. Santilli, G. Grillea, F. Lena, L. Meglio, N. Modugno (Pozzilli, Italy)

1:45pm-3:15pm: CR6-interacting factor1 Deficiency in Dopamine Neurons Triggers Early-onset Parkinsonism in Mice

I. Ryu, J. Han, Y. Jang, S.J. Kim, j. Kim, M.J. Lee, X. Ju, M.J. Ryu, S.-Y. Choi, W. Chung, E. Oh, G.R. Kweon (Daejeon, Republic of Korea)

1:45pm-3:15pm: Deep Brain Stimulation (DBS) battery longevity of Medtronic Activa SC is briefer than preceding Soletra models, a within subject analysis

E. Hargreaves, R. Patel, R. DiPaola, S. Wong, D. Caputo, S. Danish (New Brunswick, NJ, USA)

1:45pm-3:15pm: Detection of Early Changes in Microbiota Composition in Prodromal Parkinson’s Disease

J. Boertien, T. Van Laar (Groningen, Netherlands)

1:45pm-3:15pm: Development of nano-formulation containing crocetin for the protective and beneficial effect against 6-hydroxydopamine induced Parkinson’s disease model via altered the genetic backgrounds

V. Kumar, A. Verma, P. Bhatt (Allahabad, India)

1:45pm-3:15pm: Disease-modification in Translational Models of Parkinson’s disease by the Rho Kinase Inhibitor Fasudil

L. Tönges, L. Tatenhorst, J. Koch, T. Outeiro, M. Zweckstetter, M. Bähr, P. Lingor (Bochum, Germany)

1:45pm-3:15pm: Does cerebellar dysfunction contribute to tremor in Parkinson’s disease?

E. Batzianouli, M. Pagliaro, D. Benninger (Lausanne, Switzerland)

1:45pm-3:15pm: Dopamine substitution restores effective connectivity between prefrontal and premotor areas in Parkinson’s disease

P. Loehrer, F. Nettersheim, F. Jung, I. Weber, C. Huber, T. Dembek, E. Pelzer, M. Tittgemeyer, L. Timmermann (Marburg, Germany)

1:45pm-3:15pm: Dural lymphatic vasculature in human superior saggital sinus: the brain drain

N. Visanji, A. Lang, D. Munoz (Toronto, ON, Canada)

1:45pm-3:15pm: Dynamic stability during turning in people with Parkinson’s disease

C. Curtze, P. Fino, S. Smith, P. Carlson-Kuhta, J. Nutt, F. Horak (Portland, OR, USA)

1:45pm-3:15pm: Effectiveness of lead position with MER to determine STNs: A study of MER with DBS for quantifying the effects of DBS in Parkinson`s disease

V. Rama Raju, R. Borgohain (HYDERABAD, India)

1:45pm-3:15pm: Effects of different intensity exercises on motor function of PD rats as well as the regulation of DA

x. Liu, p. Chen, d. Qiao, m. wang (Beijing, China)

1:45pm-3:15pm: Efficient control of dopamine neuron physiology for rescuing disease phenotypes

T. Rumbell, J. Kozloski (Yorktown Heights, NY, USA)

1:45pm-3:15pm: Eight contact LFP recordings in the Subthalamic region localize beta source to the dorsal STN

I. Tamir, C. de Hemptinne, J. Ostrem, P. Starr (San Francisco, CA, USA)

1:45pm-3:15pm: Epitope mapping of CSF auto-antibodies to alpha-synuclein

R. Akhtar, J. Licata, K. Luk, D. Covell, J. Trojanowski, V. Lee (Philadelphia, PA, USA)

1:45pm-3:15pm: Evaluation of CSF cytokine profiles in people with Parkinson disease and age-matched controls.

G. Crotty, D. Vaughan, G. Moloney, G. O'Keeffe, S. O'Sullivan, A. Sullivan (Cork, Ireland)

1:45pm-3:15pm: Evaluation of serum sestrin protein in Parkinson’s disease: a plausible diagnostic marker

S. Dey, N. Rai, A. Singh, S. Shekhar, A. Dey (New Delhi, India)

1:45pm-3:15pm: Evaluation of spike sorting algorithms applied to artificial spikes and to spikes recorded from the Subthalamic Nucleus of PD patients

J. Sukiban, N. Voges, I. Weber, T. Dembek, M. Denker, M. Barbe, S. Grün, L. Timmermann (Cologne, Germany)

1:45pm-3:15pm: Evaluation of Swallowing Function in Parkinson’s Disease Patients with and without Dysphagia Complaints

E. Umay, E. Ozturk, I. Gundogdu, O. Delibas, A. Cakci, B. Gonenli, Y. Eren (Ankara, Turkey)

1:45pm-3:15pm: Exploratory Clinical study of role of cerebral dopamine neurotrophic factor (CDNF) mediating endoplasmic reticulum stress (ERS) in Parkinson Disease

K. Terpstra, R. Mishra, S. Chiu (Hamilton, ON, Canada)

1:45pm-3:15pm: Exposure to bifenthrin contributes to Parkinson’s disease in mouse model

C. Han, S. Liu, J. Huang, L. Liu, K. Ma, X. Guo, S. Guo, L. Wang, Y. Shen, Y. Xia, F. Wan, N. Xiong, T. Wang (Wuhan, China)

1:45pm-3:15pm: Expression of late cell cycle markers in Parkinson Disease and Lewy Body Dementia

I. Martinez-Valbuena, R. Valenti-Azcarate, M.M. Carmona-Abellan, I. Marcilla-Garcia, I. Gaston-Zubimendi, G. Marti-Andres, M.-T. Tuñon-Alvarez, M.-R. Luquin-Piudo (Pamplona, Spain)

1:45pm-3:15pm: Extracellular alpha-synuclein internalizes into cells by hijacking endocytic trafficking of dopamine transporter

J. Kobayashi, T. Hasegawa, N. Sugeno, S. Yoshida, A. Kikuchi, A. Takeda, M. Aoki (Sendai, Japan)

1:45pm-3:15pm: Feasibility and Safety of Multisite Tissue and Biofluid Sampling for Alpha-Synuclein in Parkinson’s Disease: The Systemic Synuclein Sampling Study (S4)

C. Linder, B. Mollenhauer, C. Coffey, T. Beach, T. Foroud, C. Adler, H. Riss, D. Ecklund, C. Caspell-Garcia, K. Dave, S. Deshpande, S. Lasch, V. Arnedo, L. Riley, C. Kopil, D. Jennings, L. Chahine (Philadelphia, PA, USA)

1:45pm-3:15pm: Firing rate and proportion of subthalamic oscillatory neurons increase associated with more advanced Parkinson’s Disease

P. Zhuang, M. Hallett, Y. Wen, Y. Zhang, J. Li, Y. Li (Beijing, China)

1:45pm-3:15pm: Freezing of gait in Parkinson’s disease consists of unique pressure-based gait phase transitions

L. Luo, D. Zanotto, F. Maget, B. Xu, S. Agrawal, P. Mazzoni (New York, NY, USA)

1:45pm-3:15pm: Fundamental limit of the alpha-synuclein immunohistochemistry using the endoscopic biopsy from the gastrointestinal tract as a biomarker for Parkinson disease: a case-control study

C.W. Shin, S.-H. Park, J.Y. Yun, J.H. Shin, H.-K. Yang, H.-J. Lee, S.-H. Kong, Y.J. Jung, G. Shen, H. Kim (Seoul, Republic of Korea)

1:45pm-3:15pm: Gait disturbance and olfactory dysfunction is associated with central cholinergic dysfunction in early Parkinson’s disease

E. Oh, Y. Lim, S. Park (Daejeon, Republic of Korea)

1:45pm-3:15pm: GBA mRNA is diminished in brain and blood of Lewy body diseases

K. Beyer, J. Campdelacreu, L. Ispierto, D. Vilas, R. Reñé, R. Alvarez (Badalona, Spain)

1:45pm-3:15pm: Genetic knock-down of HDAC4 attenuates rotenone-induced abnormal expression of α-synuclein by affecting autophagic flux in SH-SY5Y Cells

L. Wang, J. Huang, L. Liu, C. Han, K. Ma, X. Guo, S. Guo, Y. Shen, Y. Xia, F. Wan, N. Xiong, T. Wang (Wuhan, China)

1:45pm-3:15pm: Goal-Directed Movement in Idiopathic Parkinson’s Disease and the effect of Parkin Mutations

C. Fearon, T. Munteanu, D. Birsanu, L. Newman, B. Quinlivan, i. killane, B. Magennis, J. Butler, R. Reilly, T. Lynch (Dublin 7, Ireland)

1:45pm-3:15pm: High-mobility group box 1 from astrocytes upregulates TH expression to maintain dopaminergic neurons via JNK pathway in human Parkinson’s disease patients and MPTP induced mouse model

S.J. Kim, M.J. Ryu, J. Han, Y. Jang, J. Kim, M.J. Lee, I. Ryu, X. Ju, W. Chung, E. Oh, G.R. Kweon (Daejeon, Republic of Korea)

1:45pm-3:15pm: Impacts of CSF kynurenine pathway on neuroinflammaion in patients with Parkinson’s disease

K. Iwaoka, T. Maeda, Y. Terayama (Morioka, Japan)

1:45pm-3:15pm: Impaired intracortical inhibition is associated with reduced hand dexterity in Parkinson’s disease patients

S. Filipović, A. Kačar, S. Milanović, M. Ljubisavljević, V. Kostić (Beograd, Serbia)

1:45pm-3:15pm: Impaired stress-induced mitophagy in parkinsonian LRRK2(R1441G) knockin mutant mice

P.W.-l. Ho, C.S.-c. Lam, H.-f. Liu, G.C.-t. Leung, L. Li, M.H.-w. Kung, D. Ramsden, S.-l. Ho (Hong Kong, Hong Kong)

1:45pm-3:15pm: In silico predictive analytics: accelerating identification of potential disease-modifying compounds for Parkinson’s disease

N. Visanji, A. Lacoste, S. Spangler, E. Argentinis, S. Ezell, C. Marras, L. Kalia (Toronto, ON, Canada)

1:45pm-3:15pm: Increased and symmetric expression of rigidity in early Parkinson’s disease with abnormal REM sleep without atonia

M. Petrucci, S. Amundsen Huffmaster, C. Lu, P. Tuite, M. Howell, C. MacKinnon (Minneapolis, MN, USA)

1:45pm-3:15pm: Increased appendicular lean body mass is associated with increased cerebral cholinergic innervation in Parkinson disease

J. Chua, M. Müller, M. Beaulieu, S. Nejad-Davarani, N. Bohnen (Ann Arbor, MI, USA)

1:45pm-3:15pm: Increased bilirubin levels in Parkinson’s disease from southern Spain.

D. Macias Garcia, D. Macias Garcia, C. Mendez Barrio, S. Jesus, M.A. Labrador Espinosa, M. Bernal Escudero, L. Vargas Gonzalez, A. Adarmes Gomez, F. Carrillo, M. Carballo, P. Gómez-Garre, P. Mir (Seville, Spain)

1:45pm-3:15pm: Information transfer between subthalamic area and forearm muscles during tonic muscle activity in Parkinson’s patients

I. Weber, E. Florin, M. von Papen, L. Timmermann (Marburg, Germany)

1:45pm-3:15pm: Inhibition of mitochondrial complex I synthesis by chloramphenicol mitigates dopaminergic neuronal cell loss in PQ-induced parkinsonism

S.J. Kim, J. Han, Y. Jang, J. Kim, M.J. Lee, I. Ryu, X. Ju, M.J. Ryu, W. Chung, J.Y. Heo (Daejeon, Republic of Korea)

1:45pm-3:15pm: Insulin Resistance In Non-Diabetic People With Parkinson’s Disease

M. Tagliati, E. Tan, J. Eskenazi, C. Basile, E. Hogg (Los Angeles, CA, USA)

1:45pm-3:15pm: Interaction between PLK2 ( Polo-like kinase-2) and alpha-synuclein in the non-human primate MPTP model of Parkinson disease

R. Valenti-Azcarate, I. Martinez-Valbuena, M.-M. Carmona-Abellan, I. Marcilla-Garcia, G. Marti-Andres, M.R. Luquin-Piudo (Pamplona, Spain)

1:45pm-3:15pm: Intracortical plasticity is preserved in de novo Parkinson’s disease: a tSMS study.

M. Dileone, V. Catanzaro, J. Obeso, G. Foffani (Mostoles, Spain)

1:45pm-3:15pm: Is the GBA2 a new modifier for Gauchers’s disease and GBA1-related Parkinson’s disease?

E. Nakanishi, N. Uemura, H. Akiyama, M. Kinoshita, H. Yamakado, S. Takeda, Y. Hirabayashi, R. Takahashi (kyoto, Japan)

1:45pm-3:15pm: Listen to your heart: ordinal pattern statistics reveal altered cardiac rhythm dynamics in LRRK2-nonmanifesting carriers

C. Carricarte Naranjo, C. Marras, N. Visanji, A. Lang, L. Sanchez-Rodriguez, A. Machado García (La Habana, Cuba)

1:45pm-3:15pm: Longitudinal study of freezing of gait in patients with Parkinson’s disease

M. Sawada, K. Wada-Isoe, S. Tagashira, K. Nakashima (Tottori, Japan)

1:45pm-3:15pm: Mesencephalic astrocyte-derived neurotrophic factor alleviated 6-OHDA-induced cell damage via ROS-AMPK/mTOR mediated autophagic inhibition

J. Zhang, Q. Cai, M. Jiang, Y. Liu, H. Gu, J. Guo, H. Sun, J. Fang (Shanghai, China)

1:45pm-3:15pm: Mesencephalic astrocyte-derived neurotrophic factor reduces cell apoptosis via upregulating HSP70 in SHSY-5Y cells

H. Sun, M. Jiang, J. Zhang, L. Feng, Y. Liu, Z. Nie, J. Fang, L. Jin (Shanghai, China)

1:45pm-3:15pm: Metabolic syndrome: Its link with motor function of Parkinson’s disease (PD)

H. Chan, Y. Cheung, D. Chau, V. Lo, C. Woo, S. Tse, T. Fung, W. Fong (Hong Kong, Hong Kong)

1:45pm-3:15pm: Metabolomic biomarkers strongly differentiate PD from healthy controls (HCs) in BioFIND study* specimens

P. LeWitt, J. Li, M. Lu, K.-H. Wu, Y. Zhou, I. Datta, L. Guo, B. Investigators (West Bloomfield, MI, USA)

1:45pm-3:15pm: Modeling Parkinson’s disease pathology by combined injection of fibrilar and monomeric α-synuclein in rat brain

P. Thakur, L. Breger, M. Lundblad, O. Wan, B. Mattsson, K. Luk, V. Lee, J. Trojanowski, A. Björklund (Frankfurt, Germany)

1:45pm-3:15pm: Motor effects induced by D1- or D2-like receptor agonists in experimental parkinsonism.

L. Andreoli, C. Alcacer, I. Sebastianutto, A. Cenci Nilsson (Lund, Sweden)

1:45pm-3:15pm: Mutant DNAJC13 modulates accumulation and toxicity of alpha-synuclein through altered endosomal trafficking in cell and fly models of Parkinson’s disease

T. Hasegawa, S. Yoshida, M. Suzuki, J. Kobayashi, N. Sugeno, K. Sekiguchi, M. Edura, A. Kikuchi, A. Takeda, Y. Nagai, M. Aoki (Sendai, Japan)

1:45pm-3:15pm: Neuroinflammation in the substantia nigra is triggered by synucleinopathy and precedes nigral degeneration

M. Duffy, T. Collier, K. Luk, M. Tansey, K. Paumier, D. Fischer, N. Polinski, C. Kemp, C. Sortwell (Grand Rapids, MI, USA)

1:45pm-3:15pm: Neuroprotective effect of α-Mangostin in restoration mitochondrial function in MPTP-Induced Parkinson’s disease in mice

A. Prakash, A.B. Majeed, K. Ramasamy, M. Hasan (Baltimore, MD, USA)

1:45pm-3:15pm: Neuroprotective Potency of Tetrahydroisoquinoline a Novel Ayurveda Molecule in Experimental Parkinson’s Disease

R. Banerjee, D. Nthenge-Ngumbau, R. Singh, P. Jaisankar, K. Mohanakumar, S. Biswas (Kolkata, India)

1:45pm-3:15pm: New device HANABI (HANdai Amyloid Burst Inducer) is a rapid and sensitive detecting system of α synuclein fibril in CSF from Parkinson’s disease patients

K. Ikenaka, K. Araki, M. So, S. Hashimoto, T. Tokuda, Y. Goto, H. Mochizuki (Suita, Japan)

1:45pm-3:15pm: Objective gait parameters as a noninvasive biomarker for freezing of gait in Parkinson’s disease patients

J. Shah, T. Virmani (Little Rock, AR, USA)

1:45pm-3:15pm: Objective identification of freezing of gait in Parkinson’s disease patients using a triaxial accelerometer

Y. Okuma, H. Mitoma, M. Yoneyama (Izunokuni-city, Japan)

1:45pm-3:15pm: Optimization of Synucleinopathy and Nigrostriatal Degeneration Induced by Injection of Alpha-Synuclein Preformed Fibrils into Rat Striatum

C. Sortwell, T. Collier, M. Duffy, K. Luk, C. Kemp, N. Kanaan, K. Paumier, J. Patterson (Grand Rapids, MI, USA)

1:45pm-3:15pm: Parkinson ‘ s disease and Peripheral Nervous System : Wax and Waning Non-motor offs and Levodopa-use Topics

s.g. echebarria mendieta (-, Spain)

1:45pm-3:15pm: Parkinson’s disease disrupts motor skill learning that requires improvement of a speed-accuracy trade-off

C. Kim, A. Zimnik, U. Kang, P. Mazzoni (New York, NY, USA)

1:45pm-3:15pm: Parkinson’s Disease-Like Pathology in the Rat Brain and Colon Following Methamphetamine Self-Administration

B. Bradaric, A. Persons, S. Kousik, L. Kelly, S. Graves, T.C. Napier (Chicago, IL, USA)

1:45pm-3:15pm: Parkinsonism in the very old – A clinicopathological study

A. Rajput, E. Rajput (Saskatoon, SK, Canada)

1:45pm-3:15pm: Pharmacological modulation of mGluR5 improves dyskinesias mediated by D1 but not D2 receptor stimulation.

I. Sebastianutto, N. Maslava, L. Di Menna, F. Nicoletti, M. Cenci (Lund, Sweden)

1:45pm-3:15pm: Phosphodiesterases and striatal pathways in Parkinson’s disease

H. Wilson, G. Pagano, F. Niccolini, N. Muhlert, C. Coello, A. Tziortzi, G. Searle, R. Gunn, E. Rabiner, T. Foltynie, M. Politis (London, United Kingdom)

1:45pm-3:15pm: Potential of non-invasive brain stimulation to ameliorate freezing of gait in Parkinson’s disease: A deep repetitive TMS randomized, double-blinded, cross-over pilot study

M. Dagan, T. Herman, A. Mirelman, N. Giladi, J. Hausdorff (Tel Aviv, Israel)

1:45pm-3:15pm: Premovement betaband event-related desynchronization related to simple lower limb movement and simulated gait initiation in Parkinson’s disease patients: MEG study

J.Y. Yun, J.S. Kim, H.W. Lee (Seoul, Republic of Korea)

1:45pm-3:15pm: Prognostic relevance and predictive ability of data-driven PD subtypes in the Longitudinal and Biomarker Studies in Parkinson’s disease (LABS-PD)

T. Mestre, S. Eberly, C. Tanner, D. Grimes, A. Lang, D. Oakes, C. Marras (Ottawa, ON, Canada)

1:45pm-3:15pm: Quantifying postural stability differences in people with Parkinson’s disease with and without freezing of gait, using body-worn sensors

P. Carlson-Kuhta, M. El-Gohary, M. Mancini, F. Horak, J. Huisinga (Portland, OR, USA)

1:45pm-3:15pm: Regulation of aberrant striatal oscillations by glutamate receptor blockade in parkinsonian non-human primates

A. Singh, S. Papa (Minneapolis, MN, USA)

1:45pm-3:15pm: Relationship between the presence of colonic a-synuclein and MDS research criteria for prodromal PD in patients without manifest motor parkinsonism (PARCAS study)

M. Skorvanek, Z. Ladomirjakova, V. Han, N. Lesko, E. Feketeova, B. Kolarova, B. Repkova, Z. Urbancikova, A. Vargova, L. Gombosova, M. Zakuciova, E. Veseliny, F. Trebuna, E. Mechirova, Z. Gdovinova (Kosice, Slovakia)

1:45pm-3:15pm: Relationship of metabolic markers in Parkinson’s disease

N. Alsomali, A. Mujtaba, A. AlSamrani, S. Marar, T. Mohammad (Riaydh, Saudi Arabia)

1:45pm-3:15pm: Reproducibility of data-driven Parkinson’s disease subtypes for clinical research using a Delphi process for expert-based consensus.

T. Mestre, S. Eberly, C. Tanner, A. Lang, D. Grimes, D. Oakes, C. Marras (Ottawa, ON, Canada)

1:45pm-3:15pm: Role of the subthalamic nucleus and globus pallidus internus in response inhibition during masked prime tasks in human

A. Singh, I. Niazi, V. Sharma, K. Boetzel (Minneapolis, MN, USA)

1:45pm-3:15pm: Salivary Alpha-Synuclein in Aging

G. Vivacqua, A. Fabbrini, A. Suppa, R. Mancinelli, G. Fabbrini, C. Colosimo, A. Berardelli (Rome, Italy)

1:45pm-3:15pm: Serum lipid profile in Parkinsons disease patients from Southern Spain

C. Mendez Barrio, D. Macias Garcia, S. Jesus, M.A. Labrador Espinosa, L. Vargas Gonzalez, M. Bernal Escudero, A. Adarmes Gomez, F. Carrillo Garcia, M. Carvallo Cordero, P. Gomez Garr, P. Mir (Seville, Spain)

1:45pm-3:15pm: Serum soluble transferrin receptor levels correlate with the Hoehn & Yahr stage of Parkinson disease progression

P. Costa-Mallen, S.-C. Hu, P. Agarwal (Kenmore, WA, USA)

1:45pm-3:15pm: Skin nerve phosphorylated α-synuclein deposits in idiopathic REM sleep behavior disorder.

E. Antelmi, V. Donadio, G. Plazzi, R. Liguori (Bologna, Italy)

1:45pm-3:15pm: Successful passive monitoring of early-stage Parkinson’s disease patient mobility in Phase I RG7935/PRX002 clinical trial with smartphone sensors

F. Lipsmeier, I. Fernandez Garcia, D. Wolf, T. Kilchenmann, A. Scotland, J. Schjodt-Eriksen, W.-Y. Cheng, J. Siebourg-Polster, L. Jin, J. Soto, L. Verselis, M. Martin Facklam, F. Boess, M. Koller, M. Grundman, M. Little, A. Monsch, R. Postuma, A. Gosh, T. Kremer, K. Taylor, C. Czech, C. Gossens, M. Lindemann (Basel, Switzerland)

1:45pm-3:15pm: Synthesis and pharmacological evaluation of 16-aryldieno steroids as anti-parkinsonian agents in LPS induced Neuroinflammation Model of Rat

R. Bansal, R. Singh (Chandigarh, India)

1:45pm-3:15pm: Targeted overexpression of A53T-alpha-synuclein induces progressive neurodegeneration and electrophysiological changes of noradrenergic locus coeruleus neurons – a preclinical model of Parkinson’s disease

M. Henrich, L. Matschke, A. Stoehr, W.-H. Chiu, B. Lee, F. Geibl, J. Koprich, N. Decher, W. Oertel (Marburg, Germany)

1:45pm-3:15pm: The comparison of urine microvesicle reflecting gut microbiome between Parkinson’s disease and healthy control

J. Park, S. Park, W. Jang, J.S. Kim, J. Yoon, E. Oh (Busan, Republic of Korea)

1:45pm-3:15pm: The effects of dual task on the finger tapping performance of Parkinson’s disease.

A. Miyake, T. Yamamoto, H. Kawasaki, T. Furuya, T. Fukuoka, K. Takahashi, N. Tamura, N. Araki (irumagun moroyama town, Japan)

1:45pm-3:15pm: The nature of postural tremor in Parkinson’s disease

M. Dirkx, H. Zach, M. Hallet, R. Helmich (Nijmegen, Netherlands)

1:45pm-3:15pm: The novel Parkinson´s disease locus RIT2 and alpha-synuclein function in intersecting pathways

M. Volta, J. Obergasteiger, C. Überbacher, C. Ascione, C. Corti, A. Hicks, P. Pramstaller (Bolzano, Italy)

1:45pm-3:15pm: The tricyclic antidepressant medication nortriptyline inhibits alpha-synuclein accumulation, aggregation and toxicity in multiple in vitro and in vivo models.

T. Collier, L. Lapidus, C. Sortwell, C. Justman, P. Lansbury, K. Paumier (Grand Rapids, MI, USA)

1:45pm-3:15pm: The value of the Tau/α-synuclein ratio and TNF-α in cerebrospinal fluid, and of plasma IL-6, in the diagnosis and prognosis of Parkinson’s disease

M. Delgado-Alvarado, B. Gago, A. Gorostidi, H. Jimenez-Urbieta, R. Dacosta-Aguayo, I. Navalpotro-Gómez, J. Ruiz-Martínez, A. Bergareche, J. Martí-Massó, P. Martínez-Lage, A. Izagirre, M. Rodríguez-Oroz (San Sebastián, Spain)

1:45pm-3:15pm: Verticality Perception Differentially Correlates with Pisa Syndrome in Parkinson’s Disease

Y.E. Huh, W.-H. Chung, K. Kim, J.W. Cho (Seongnam-si, Republic of Korea)

1:45pm-3:15pm: Vitamin D in the Parkinson’s Associated Risk (PARS) Study

M. Fullard, S. Xie, K. Marek, M. Stern, D. Jennings, A. Siderowf, A. Chen-Plotkin (Philadelphia, PA, USA)

« View all sessions from the 21st International Congress.